Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results

Advanced clinical development in two broad areas of autoimmune disease: rheumatology and neurologyStrong balance sheet, bolstered by recent public offering, expected to fund operations into...

Related Keywords

Germany ,United States ,George Thampy ,Kyverna Ingenui ,Peter Maag ,Elevatebio Basecamp ,Company Annual Report On Form ,Prnewswire Kyverna Therapeutics Inc ,Nasdaq ,Kyverna Therapeutics Inc ,Chief Executive Officer ,Recent Business ,Track Designations ,Year Ended December ,Kyverna Therapeutics ,Risk Factors ,Annual Report ,Ended December ,